Ahrens S P, Farmer M V, Williams D L, Willoughby E, Jiang K, Block G A, Visser W H
Merck & Co., Inc., West Point, PA, USA.
Cephalalgia. 1999 Jun;19(5):525-30. doi: 10.1046/j.1468-2982.1999.019005525.x.
Rizatriptan is a potent, highly selective 5HT1B/1D agonist with rapid onset of action for acute treatment of migraine. Rizatriptan wafer is a novel, freeze-dried dosage formulation of rizatriptan which rapidly disintegrates on the tongue, is swallowed with saliva, and may be taken without liquids. The efficacy and tolerability of rizatriptan wafer were examined in a placebo-controlled, double-blind, outpatient study in 555 migraineurs. The primary efficacy endpoint was pain relief at 2 h. From 30 min onwards, significantly more patients experienced pain relief and became pain-free after rizatriptan 10-mg wafer compared to placebo. At 2 h, the percentage of patients with pain relief was significantly higher after rizatriptan 10-mg wafer (74%), 5-mg wafer (59%) compared with placebo (28%). Rizatriptan 10-mg wafer was superior to rizatriptan 5-mg wafer on pain relief at 1.5 and 2 h (p < 0.05). Significantly more patients were pain-free at 2 h after rizatriptan 10-mg wafer (42%), 5-mg wafer (35%) compared with placebo (10%). Both doses of rizatriptan wafer were well tolerated. Rizatriptan wafer is a convenient, highly effective new formulation for acute treatment of migraine.
利扎曲普坦是一种强效、高选择性的5HT1B/1D激动剂，用于偏头痛急性治疗时起效迅速。利扎曲普坦片是利扎曲普坦的一种新型冻干剂型，可在舌上迅速崩解，随唾液咽下，无需用水送服。在一项针对555名偏头痛患者的安慰剂对照、双盲门诊研究中，对利扎曲普坦片的疗效和耐受性进行了检验。主要疗效终点为2小时时的疼痛缓解情况。从30分钟起，与安慰剂相比，服用10毫克利扎曲普坦片后，有更多患者出现疼痛缓解并达到无痛状态。在2小时时，服用10毫克利扎曲普坦片（74%）、5毫克利扎曲普坦片（59%）后疼痛缓解的患者百分比显著高于安慰剂组（28%）。在1.5小时和2小时时，10毫克利扎曲普坦片在疼痛缓解方面优于5毫克利扎曲普坦片（p<0.05）。服用10毫克利扎曲普坦片（42%）、5毫克利扎曲普坦片（35%）后2小时时达到无痛的患者明显多于安慰剂组（10%）。两种剂量的利扎曲普坦片耐受性均良好。利扎曲普坦片是一种用于偏头痛急性治疗的方便、高效的新剂型。
